LH

SEC source: 0001127602-24-028580 · form4.xml · derivative · entry 4

EISENBERG GLENN A · CIK 0001222831 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,923 shares

Expires 2031-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan.

F3 · derivative.exercise_price: Represents amounts automatically adjusted based on the final adjustment ratio applied to equity awards in connection with the spin-off of Fortrea Holdings Inc. ("Fortrea") by Labcorp Holdings Inc. ("LHI"), calculated pursuant to the terms of the Employee Matters Agreement by and between LHI and Fortrea.

F3 · shares: Represents amounts automatically adjusted based on the final adjustment ratio applied to equity awards in connection with the spin-off of Fortrea Holdings Inc. ("Fortrea") by Labcorp Holdings Inc. ("LHI"), calculated pursuant to the terms of the Employee Matters Agreement by and between LHI and Fortrea.

F4 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column.

SEC source: 0001127602-24-028580 · form4.xml · nonDerivative · entry 3

EISENBERG GLENN A · CIK 0001222831 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,289

F1 · price: The price of $240.4279 per share represents a weighted average of sales prices ranging from $240.015 to $240.94 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-24-028580 · form4.xml · nonDerivative · entry 2

EISENBERG GLENN A · CIK 0001222831 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-028580 · form4.xml · nonDerivative · entry 1

EISENBERG GLENN A · CIK 0001222831 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,212

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-028577 · form4.xml · nonDerivative · entry 1

Gilliland Dwight Gary · CIK 0001603769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,712

SEC source: 0001127602-24-028052 · form4.xml · derivative · entry 3

Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,015 shares

Expires 2030-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan.

F3 · derivative.exercise_price: Represents amounts automatically adjusted based on the final adjustment ratio applied to equity awards in connection with the spin-off of Fortrea Holdings Inc. ("Fortrea") by Labcorp Holdings Inc. ("LHI"), calculated pursuant to the terms of the Employee Matters Agreement by and between LHI and Fortrea.

F3 · shares: Represents amounts automatically adjusted based on the final adjustment ratio applied to equity awards in connection with the spin-off of Fortrea Holdings Inc. ("Fortrea") by Labcorp Holdings Inc. ("LHI"), calculated pursuant to the terms of the Employee Matters Agreement by and between LHI and Fortrea.

F4 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column.

SEC source: 0001127602-24-028052 · form4.xml · nonDerivative · entry 2

Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,318.5

F1 · price: The price of $238.9055 per share represents a weighted average of sales prices ranging from $238.822 to $239.410 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-24-028052 · form4.xml · nonDerivative · entry 1

Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,990

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-027946 · form4.xml · nonDerivative · entry 1

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,669.847

SEC source: 0001127602-24-027132 · form4.xml · nonDerivative · entry 1

Schechter Adam H · CIK 0001376841 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,441

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001127602-24-026417 · form4.xml · derivative · entry 1

Oyegunwa Akinbolade · CIK 0002042869 · EVP, CIO & CTO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,082

Underlying: Common Stock · 1,110 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on November 1, 2025.

F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on November 1, 2025.

F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-24-026415 · form4.xml · derivative · entry 1

Bailey Megan D. · CIK 0001975682 · EVP, Pres, Central Labs & Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,517

Underlying: Common Stock · 1,110 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on November 1, 2025.

F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on November 1, 2025.

F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-24-025961 · form4.xml · nonDerivative · entry 1

ANDERSON KERRII B · CIK 0001227159 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,722

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001127602-24-022676 · form4.xml · nonDerivative · entry 1

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,669.847

F1 · balance_after: Amount includes 32.868 shares acquired on June 28, 2024 under the Labcorp Holdings Inc. Amended and Restated 2016 Employee Stock Purchase Plan.

SEC source: 0001127602-24-022401 · form4.xml · nonDerivative · entry 3

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,289

F3 · price: The price of $224.5488 per share represents a weighted average of sales prices ranging from $224.25 to $224.91 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-24-022401 · form4.xml · nonDerivative · entry 2

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,360

F2 · price: The price of $223.6169 per share represents a weighted average of sales prices ranging from $223.25 to $224.162 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-24-022401 · form4.xml · nonDerivative · entry 1

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,310

F1 · price: The price of $222.6494 per share represents a weighted average of sales prices ranging from $222.25 to $223.15 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-24-021913 · form4.xml · nonDerivative · entry 2

ANDERSON KERRII B · CIK 0001227159 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,722

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001127602-24-021913 · form4.xml · nonDerivative · entry 1

ANDERSON KERRII B · CIK 0001227159 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,308

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001127602-24-021768 · form4.xml · nonDerivative · entry 2

BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,921

F2 · price: The price of $228.9485 per share represents a weighted average of sales prices ranging from $228.53 to $229.525 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-24-021768 · form4.xml · nonDerivative · entry 1

BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,769

F1 · price: The price of $229.785 per share represents a weighted average of sales prices ranging from $229.74 to $229.87 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-24-018228 · form4.xml · derivative · entry 2

Rothman Paul · CIK 0001601332 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 944

Underlying: Common Stock · 717 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

F2 · derivative.exercise_date: The Restricted Stock Units vested fully on June 6, 2024.

F2 · derivative.expiration_date: The Restricted Stock Units vested fully on June 6, 2024.

F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-24-018228 · form4.xml · nonDerivative · entry 1

Rothman Paul · CIK 0001601332 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 717

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

SEC source: 0001127602-24-015541 · form4.xml · nonDerivative · entry 2

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,636.979

SEC source: 0001127602-24-015541 · form4.xml · nonDerivative · entry 1

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,836.979

SEC source: 0001127602-24-013993 · form4.xml · nonDerivative · entry 2

ANDERSON KERRII B · CIK 0001227159 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,722

SEC source: 0001127602-24-013993 · form4.xml · nonDerivative · entry 1

ANDERSON KERRII B · CIK 0001227159 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,972

SEC source: 0001127602-24-013820 · form4.xml · derivative · entry 3

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,229 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Performance Share represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F3 · shares: Amount includes an additional 1,059 Performance Shares resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea Holdings Inc. ("Fortrea").

F1 · price: Each Performance Share represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F4 · derivative.exercise_date: The Performance Shares vested in full upon the filing of the Company's Quarterly Report on Form 10-Q for the first quarter of 2024, subject to both continued service and satisfaction of a performance condition related to the spin-off of Fortrea.

F3 · derivative.underlying_shares: Amount includes an additional 1,059 Performance Shares resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea Holdings Inc. ("Fortrea").

SEC source: 0001127602-24-013820 · form4.xml · nonDerivative · entry 2

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,289

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-24-013820 · form4.xml · nonDerivative · entry 1

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,785

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Performance Share represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

SEC source: 0001127602-24-013789 · form4.xml · nonDerivative · entry 1

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,087.2194

F1 · price: The price of $204.329 per share represents a weighted average of sales prices ranging from $204.291 to $204.43 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-24-013046 · form4.xml · derivative · entry 3

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,477

Underlying: Common Stock · 10,229 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units vested in full on April 15, 2024.

F3 · derivative.expiration_date: The Restricted Stock Units vested in full on April 15, 2024.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-24-013046 · form4.xml · nonDerivative · entry 2

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,556

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-24-013046 · form4.xml · nonDerivative · entry 1

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,052

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-24-012006 · form4.xml · nonDerivative · entry 1

Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,036.1426

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001127602-24-012005 · form4.xml · nonDerivative · entry 1

Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,975

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001127602-24-012004 · form4.xml · derivative · entry 3

Bailey Megan D. · CIK 0001975682 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,407

Underlying: Common Stock · 205 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in two equal installments beginning on April 1, 2024.

F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in two equal installments beginning on April 1, 2024.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-24-012004 · form4.xml · nonDerivative · entry 2

Bailey Megan D. · CIK 0001975682 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 436

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-24-012004 · form4.xml · nonDerivative · entry 1

Bailey Megan D. · CIK 0001975682 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 505

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0000920148-24-000025 · primary_doc.xml · nonDerivative · entry 3

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,636.979

F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0000920148-24-000025 · primary_doc.xml · derivative · entry 4

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,190

Underlying: Common Stock · 6,158 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F4 · derivative.exercise_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.

F4 · derivative.expiration_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.

F5 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person.

SEC source: 0000920148-24-000025 · primary_doc.xml · nonDerivative · entry 2

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,189.979

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0000920148-24-000025 · primary_doc.xml · nonDerivative · entry 1

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,794.979

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

SEC source: 0000920148-24-000023 · primary_doc.xml · derivative · entry 3

Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,065

Underlying: Common Stock · 11,556 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F3 · derivative.exercise_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.

F3 · derivative.expiration_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.

F4 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person.

SEC source: 0000920148-24-000023 · primary_doc.xml · nonDerivative · entry 2

Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,513.1426

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0000920148-24-000023 · primary_doc.xml · nonDerivative · entry 1

Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,592.1426

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

SEC source: 0000920148-24-000024 · primary_doc.xml · derivative · entry 3

Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,740

Underlying: Common Stock · 11,556 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F3 · derivative.exercise_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.

F3 · derivative.expiration_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.

F4 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person.

SEC source: 0000920148-24-000024 · primary_doc.xml · nonDerivative · entry 2

Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,881.0428

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0000920148-24-000024 · primary_doc.xml · nonDerivative · entry 1

Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,942.0428

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

SEC source: 0000920148-24-000022 · primary_doc.xml · derivative · entry 3

Schechter Adam H · CIK 0001376841 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,842

Underlying: Common Stock · 72,435 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F3 · derivative.exercise_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.

F3 · derivative.expiration_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.

F4 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person.